IP Library Granted Patent US 12,201,757
Granted Patent B2
US 12,201,757 · App. 17/611,782 · Granted Jan 21, 2025

Photoactivated blood products and methods and apparatus for fabrication and use of same

Inventors: Nicholas William Medendorp, Jr. (Durham, NC); Katelyn Reighard Crizer (Durham, NC)
Assignee: KNOW Bio, LLC
A61M1/0259A61K35/16A61K38/1858A61M2202/0415A61M2202/0445
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,201,757
App. No.
17/611,782
Granted
Jan 21, 2025
Kind
B2
Abstract

Embodiments provide methods and apparatus for fabricating blood products, such as platelet-rich plasma, containing elevated concentrations of growth factors such as platelet derived growth factor. The platelet-rich plasma can be autologous, and the concentration of growth factors (e.g., platelet derived growth factor) is elevated relative to other samples isolated from the same subject. The platelet-rich plasma can be used to promote tissue regeneration, including wound healing, joint repair, hair growth, and the like. The compositions can be combined with stem cells and used to treat disorders otherwise treated with stem cells. The growth factors present in the samples can direct the differentiation of the stem cells.

Claims (18)

1. A method of making a light-irradiated plasma product from blood, the method comprising:

(a) processing a quantity of whole blood by controlling a spectral content of light applied to the quantity of whole blood such that a concentration of a growth factor in the quantity of whole blood is increased, wherein controlling the spectral content of the applied light comprises providing light in a wavelength range of from 660 nm to 1500 nm; and

(b) extracting a plasma product including the growth factor from the processed quantity of whole blood.

2. The method of claim 1 , wherein controlling the spectral content of the applied light comprises providing light in a wavelength range from 600 nm to 900 nm and wherein the growth factor comprises a platelet-derived growth factor (PDGF).

3. The method of claim 1 , further comprising controlling a radiant energy of the applied light.

4. The method of claim 3 , wherein controlling the radiant energy of the applied light comprises controlling an exposure time of the applied light.

5. The method of claim 1 , wherein controlling the spectral content of the applied light comprises irradiating the quantity of whole blood with a solid-state light source.

6. The method of claim 5 , wherein the solid-state light source comprises a LED light source.

7. The method of claim 6 , wherein the LED light source has a maximum spectral power in a wavelength range from 600 nm to 1500 nm.

8. The method of claim 1 , wherein controlling the spectral content of the applied light further comprises irradiating a transparent vessel containing the quantity of whole blood with a spectrally-selective light source while the transparent vessel is housed in an enclosure that blocks exposure of the vessel to ambient light.

9. The method of claim 8 , wherein the spectrally-selective light source comprises an LED light source.

10. The method of claim 1 , further comprising administering a therapeutically effective amount of a composition including the plasma product to tissue of a subject in need thereof to promote tissue regeneration.

11. The method of claim 10 , wherein a concentration of the growth factor in the composition is at least 50% higher than a concentration of the growth factor in an un-irradiated sample of platelet-rich plasma isolated from a source of the quantity of whole blood.

12. The method of claim 10 , wherein the tissue regeneration comprises increased hair growth.

13. The method of claim 10 , wherein the tissue regeneration comprises reduction of skin wrinkles.

14. The method of claim 3 , wherein controlling the radiant energy of the applied light includes a radiant energy of at least 1 J/cm 2 .

15. The method of claim 3 , wherein controlling the radiant energy of the applied light includes a radiant energy of at least 10 J/cm 2 .

16. The method of claim 10 , wherein the quantity of whole blood is derived from the subject.

Assignments (3)
ENTITY OF CONVERSION Recorded May 2, 2024
From: PHOTONMD, LLC
To: PHOTONMD, INC.
Reel/Frame 067304/0303 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 30, 2024
From: CRIZER, KATELYN REIGHARD
To: PHOTONMD, LLC
Reel/Frame 067265/0018 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 22, 2024
From: MEDENDORP, NICHOLAS WILLIAM, JR.
To: KNOW BIO, LLC
Reel/Frame 067179/0120 →
Continuity (2)
Provisional Application 62852732 · May 24, 2019
Related Publication 20220233752A1 · Jul 28, 2022
References Cited (38)
US 8240312B2 · Feuerstein et al. · 2012 [cited by applicant]
US 8435273B2 · Lum et al. · 2013 [cited by applicant]
US 8838228B2 · Beisang, III et al. · 2014 [cited by applicant]
US 9901747B2 · Gamelin et al. · 2018 [cited by applicant]
US 10525275B2 · Stasko et al. · 2020 [cited by applicant]
US 10639498B2 · Enwemeka et al. · 2020 [cited by applicant]
US 10780189B2 · Randers-Pehrson et al. · 2020 [cited by applicant]
US 10981017B2 · Enwemeka et al. · 2021 [cited by applicant]
US 11266855B2 · Enwemeka et al. · 2022 [cited by applicant]
US 11318325B2 · Rezaie et al. · 2022 [cited by applicant]
US 20070262020A1 · Wang · 2007 [cited by applicant]
US 20170231901A1 · Meng · 2017 [cited by examiner]
US 20210052760A1 · Bouschbacher et al. · 2021 [cited by applicant]
US 20210196977A1 · Zhang · 2021 [cited by applicant]
US 20210346500A1 · Schikora · 2021 [cited by applicant]
US 20210402212A1 · Schupp et al. · 2021 [cited by applicant]
US 20220088409A1 · Dombrowksi et al. · 2022 [cited by applicant]
CN 102573943A · 2012 [cited by applicant]
CN 105039303A · 2015 [cited by examiner]
WO 9211057A1 · 1992 [cited by applicant]
WO 9606647A1 · 1996 [cited by applicant]
WO 2017011612A1 · 2017 [cited by applicant]
English machine translation of Wu et al., CN 105039303 A, 2015. [cited by examiner]
Second Office Action for Chinese Patent Application No. 2020800384255, mailed Jun. 14, 2023, 13 pages. [cited by applicant]
Cavallo, et al., “Platelet-Rich Plasma: The Choice of Activation Method Affects the Release of Bioactive Molecules,” Biomed Research International, vol. 2016, Article ID 6591717, 8 pages. [cited by applicant]
Dhurat, et al., “Principles and Methods of Preparation of Platelet-Rich Plasma: A Review and Author's Perspective,” Journal of Cutaneous and Aesthetic Surgery, Oct. 2014, vol. 7, Issue 4, pp. 189-197. [cited by applicant]
Erlandsson, et al., “Immature Neurons From CNS Stem Cells Proliferate in Response to Platelet-Derived Growth Factor,” The Journal of Neuroscience, vol. 21, Issue 10, May 2001, pp. 3483-3491. [cited by applicant]
Lana, et al., “Contributions for classification of platelet rich plasma—proposal of a new classification: MARSPILL,” Regenerative Medicine, vol. 12, Issue 5, Jul. 2017, pp. 565-574. [cited by applicant]
Lubart, et al., “A Possible Mechanism for the Bactericidal Effect of Visible Light,” Laser Therapy, vol. 20, Issue 1, 2011, JMLL, pp. 17-22. [cited by applicant]
Saura, et al., “An Antiviral Mechanism of Nitric Oxide: Inhibition of a Viral Protease,” Immunity, vol. 10, Issue 1, Jan. 1999, Cell Press, pp. 21-28. [cited by applicant]
Takahashi, et al., “Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors,” Cell, vol. 131, Issue 5, Nov. 2007, Elsevier Inc., pp. 861-872. [cited by applicant]
Zhevago, et al., “Pro- and Anti-inflammatory Cytokine Content in Human Peripheral Blood after Its Transcutaneous (in Vivo) and Direct (in Vitro) Irradiation with Polychromatic Visible and Infrared Light,” Photomedicine … [cited by applicant]
International Search Report and Written Opinion for International Patent Application No. PCT/US2020/034287, mailed Sep. 28, 2020, 9 pages. [cited by applicant]
Alzyoud, et al., “Effect of light-emitting diodes, platelet-rich plasma, and their combination on the activity of sheep tenocytes,” Lasers in Medical Science, vol. 34, Issue 4, Oct. 13, 2018, Springer, pp. 759-766. [cited by applicant]
Paterson, et al., “Intra-articular injection of photo-activated platelet-rich plasma in patients with knee osteoarthritis: a double-blind, randomized controlled pilot study,” BMC Musculoskeletal Disorders, vol. 17, Dec.… [cited by applicant]
First Office Action for Chinese Patent Application No. 2020800384255, mailed Dec. 2, 2022, 13 pages. [cited by applicant]
Extended European Search Report for European Patent Application No. 20814639.9, mailed Jan. 2, 2023, 8 pages. [cited by applicant]
Decision of Rejection for Chinese Patent Application No. 2020800384255, mailed Oct. 24, 2023, 9 pages. [cited by applicant]